Neurodegenerative Diseases

The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.

Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:

Identify biomarkers for PD diagnosis, early detection, patient stratification, disease progression, prognosis or response to treatment. This is the objective of the VHIP Project that the team is carrying out.
Identify new molecular targets for potential therapeutic intervention and prevention.
Develop novel therapeutic strategies with disease-modifying potential.
Unravel molecular pathways common to other neurodegenerative diseases and, in a broader sense, brain aging.

Team

Miquel Vila Bover

Head of group
Neurodegenerative Diseases
Read more

Ariadna Laguna Tuset

Predoctoral researcher
Neurodegenerative Diseases
Read more

Jordi Bove Badell

Senior researcher
Neurodegenerative Diseases
Read more

Marta Martínez Vicente

Senior researcher
Neurodegenerative Diseases
Read more

Oriol de Fabregues-Boixar Nebot

Neurodegenerative Diseases
Read more

Núria Peñuelas Peñarroya

Predoctoral researcher
Neurodegenerative Diseases
Read more

Miquel Vila Bover

Head of group
Neurodegenerative Diseases
Read more

Ariadna Laguna Tuset

Predoctoral researcher
Neurodegenerative Diseases
Read more

Jordi Bove Badell

Senior researcher
Neurodegenerative Diseases
Read more

Marta Martínez Vicente

Senior researcher
Neurodegenerative Diseases
Read more

Oriol de Fabregues-Boixar Nebot

Neurodegenerative Diseases
Read more

Núria Peñuelas Peñarroya

Predoctoral researcher
Neurodegenerative Diseases
Read more

Research lines

Alpha-synuclein involvement in Parkinson's disease

Formation and accumulation of abnormal protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein á-synuclein accumulates in several areas of the central and peripheral nervous system. Pathological á-synuclein accumulation in PD can result from (i) abnormally increased á-synuclein expression, (ii) defective intracellular clearance of á-synuclein protein, (iii) progressive self-propagation and spreading of pathological á-synuclein between interconnected brain areas. Targeting á-synuclein pathological changes may provide therapeutic benefit to delay, halt or prevent neuronal dysfunction and degeneration in PD.

IP: Miquel Vila Bover

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Miquel Vila Bover, Ariadna Laguna Tuset

Mitophagy impairment in Huntington's disease

Defective lysosomal-mediated turnover of mitochondria may play a pathogenic role in Huntington’s disease neurodegeneration.

IP: Marta Martínez Vicente

Neuromelanin and Parkinson's disease

In Parkinson's disease (PD), there is a selective degeneration of neurons that contain a dark-brown pigment called neuromelanin, especially dopaminergic neurons of the substantia nigra, which leads to the classical motor symptoms of the disease. However, the physiological significance of neuromelanin and its potential contribution to PD pathogenesis remain unknown.

IP: Miquel Vila Bover

Projects

Restabliment de l'activitat GBA en la malaltia de Parkinson mitjançant noves estratègies terapéutiques de nanoconjugació de proteïnes

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2019/PRADAS
Duration: 01/04/2020 - 31/03/2023

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: -
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124872
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/04/2023

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 31/12/2023

NIPARK Neuromelamina como diana terapéutica en la enfermedad de Parkinson y envejecimiento cerebral: abordaje por neuroimagen y estimulación cerebral

IP: Miquel Vila Bover
Collaborators: Alba Nicolau Vera
Funding agency: Instituto de Salud Carlos III
Funding: 249984.79
Reference: AC20/00121
Duration: 01/01/2021 - 31/12/2023

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

IP: Miquel Vila Bover
Collaborators: Núria Peñuelas Peñarroya, Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 88250
Reference: BES-2017-080191
Duration: 01/07/2018 - 30/11/2022

Titol Tesi Doctoral: Caracterización de la difusión lisosomal en la enfermedad de parkinson asociada a mutaciones en GBAY desarrollo de nuevas estrategias terapeuticas mediante chaperonas farmacológicas

IP: Marta Martínez Vicente
Collaborators: Marta Montpeyó Garcia-Moreno, Miriam Izquierdo Sans , Laia Perez Lasarte
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 49266
Reference: FPU18/05595
Duration: 15/10/2019 - 14/10/2022

Restabliment de l'activitat GBA en la malaltia de Parkinson mitjançant noves estratègies terapéutiques de nanoconjugació de proteïnes

Estudio de la respuesta inmune adaptativa inducida por epítopos derivados de alfa-sinucleína en pacientes con enfermedad de Parkinson: desarrollo de estrategias neuroprotectoras.

IP: Jordi Bove Badell
Collaborators: Oriol de Fabregues-Boixar Nebot
Funding agency: Instituto de Salud Carlos III
Funding: 141570
Reference: PI18/01894
Duration: 01/01/2019 - 31/12/2022

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

Development of a novel genetically-engineered humanized rodent model to study neuronal dysfunction and neurodegeneration in Parkinson's disease and brain aging

IP: Miquel Vila Bover
Collaborators: Joan Compte Barrón, Miriam Izquierdo Sans
Funding agency: Fundació "La Caixa"
Funding: 115092
Reference: CAIXA/INPHINIT/COMPTE
Duration: 01/10/2018 - 30/09/2021

Titol Tesi Doctoral: Caracterización de la difusión lisosomal en la enfermedad de parkinson asociada a mutaciones en GBAY desarrollo de nuevas estrategias terapeuticas mediante chaperonas farmacológicas

Restabliment de l'activitat GBA en la malaltia de Parkinson mitjançant noves estratègies terapéutiques de nanoconjugació de proteïnes

Títol tesi: Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación, diagnóstica y terapéutica

IP: Jordi Bove Badell
Collaborators: Laia Perez Lasarte
Funding agency: Fundación Tatiana Pérez de Guzmán el Bueno
Funding: 94000
Reference: TATIANA/PREDOC/NEURO/2016/GALIANO
Duration: 01/12/2016 - 31/12/2020

Caracterització genètica i desenvolupament de noves estratègies traslacionals en la malatia de Parkinson

IP: Marta Martínez Vicente
Collaborators: Jordi Riera Heredia, Laia Perez Lasarte
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00268
Duration: 12/03/2018 - 31/12/2020

ROL DE LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y EL ENVEJECIMIENTO CEREBRAL: ESTUDIO DEL POTENCIAL TERAPEUTICO EN NUEVOS MODELOS PRECLINICOS "HUMANIZADOS" IN VIVO

Development of a novel genetically-engineered humanized rodent model to study neuronal dysfunction and neurodegeneration in Parkinson's disease and brain aging

Sol·licitud Miguel Servet II

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 91125
Reference: CPII16/00029
Duration: 01/01/2017 - 31/12/2019

Títol tesi: Respuesta inmune adaptativa en la enfermedad de Parkinson inducida por proteoformas de alfa-sinucleína presentes en los cuerpos de Lewy: aplicación, diagnóstica y terapéutica

INCORPORACIÓ D'UN TÈCNIC DE LABORATORI PEL DESENVOLUPAMENT DE TERÀPIES NEUROPROTECTORES I EINES DE DIAGNÒSTIC PRESIMPROMÀTIC PER A LA MALALTIA DE PARKINSON

IP: Jordi Bove Badell
Collaborators: Laia Perez Lasarte
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00258
Duration: 14/03/2018 - 12/05/2019

Caracterització genètica i desenvolupament de noves estratègies traslacionals en la malatia de Parkinson

Disfunción mitocondrial en la enfermedad de Parkinson: papel de la dinámica mitocondrial

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 61544
Reference: FPU13/01339
Duration: 02/09/2014 - 31/01/2018

Rol de la neuromelanina y alfa-sinucleína en el inicio y extensión de la Enfermedad de Parkinson: potencial diagnóstico y terapéutico en nuevos modelos pre-clínicos

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI14/00613
Duration: 01/01/2015 - 31/12/2018

Estudio del rol patogénico de la disfunción autofágica en la enfermedad de Parkinson asociada a mutaciones en GBA. Desarrollo de nuevos fármacos moduladores de la autofagia como nueva estrategia terapéutica en las enfermedades neurodegenerativas.

IP: Miquel Vila Bover
Collaborators: Marta Martínez Vicente, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII15/00007
Duration: 01/01/2016 - 31/12/2018

Sol·licitud Miguel Servet II

Malalties neurodegeneratives

IP: Marta Martínez Vicente
Collaborators: Laia Perez Lasarte
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 86400
Reference: JCI-2012-13544
Duration: 15/09/2014 - 14/09/2017

Disfunción mitocondrial en la enfermedad de Parkinson: papel de la dinámica mitocondrial

Rol de la neuromelanina y alfa-sinucleína en el inicio y extensión de la Enfermedad de Parkinson: potencial diagnóstico y terapéutico en nuevos modelos pre-clínicos

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI14/00613
Duration: 01/01/2015 - 31/12/2018

Estudio del rol patogénico de la disfunción autofágica en la enfermedad de Parkinson asociada a mutaciones en GBA. Desarrollo de nuevos fármacos moduladores de la autofagia como nueva estrategia terapéutica en las enfermedades neurodegenerativas.

Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 202500
Reference: MS11/00229
Duration: 01/01/2012 - 31/12/2016

Malalties neurodegeneratives

Transcriptional profiling by Next-Generation Sequencing in pre-symptomatic, early and advanced phases of Parkinson's Disease

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Laia Perez Lasarte
Funding agency: AGAUR
Funding: 91022.4
Reference: 2013 BP_B 00113
Duration: 01/10/2014 - 30/09/2016

Disfunción mitocondrial en la enfermedad de Parkinson: papel de la dinámica mitocondrial

Altered autophagy in Huntington's disease

IP: Miquel Vila Bover
Collaborators: Marta Martínez Vicente, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 243000
Reference: MS09/00184
Duration: 01/01/2010 - 31/12/2015

Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment

Malalties neurodegeneratives

Transcriptional profiling by Next-Generation Sequencing in pre-symptomatic, early and advanced phases of Parkinson's Disease

Altered autophagy in Huntington's disease

Inici, progressió i extensió de la Malaltia de Parkinson: rol de la neuromelanina, alfa-sinucleina i cossos de Lewy

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: AGAUR
Funding: 30000
Reference: 2011FI_B 00575
Duration: 01/02/2011 - 31/01/2014

Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment

Malalties neurodegeneratives

Altered autophagy in Huntington's disease

Inici, progressió i extensió de la Malaltia de Parkinson: rol de la neuromelanina, alfa-sinucleina i cossos de Lewy

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: AGAUR
Funding: 30000
Reference: 2011FI_B 00575
Duration: 01/02/2011 - 31/01/2014

Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment

Control de calidad de las mitocondrias: implicación en la enfermedad de Parkinson

IP: -
Collaborators: Annabelle Parent
Funding agency: Instituto de Salud Carlos III
Funding: 160325
Reference: PI09/00255
Duration: 01/01/2010 - 31/12/2013

Altered autophagy in Huntington's disease

Inici, progressió i extensió de la Malaltia de Parkinson: rol de la neuromelanina, alfa-sinucleina i cossos de Lewy

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: AGAUR
Funding: 30000
Reference: 2011FI_B 00575
Duration: 01/02/2011 - 31/01/2014

Neuroprotective strategies and biomarkers in Parkinson's disease based on lysosomal impairment

Control de calidad de las mitocondrias: implicación en la enfermedad de Parkinson

IP: -
Collaborators: Annabelle Parent
Funding agency: Instituto de Salud Carlos III
Funding: 160325
Reference: PI09/00255
Duration: 01/01/2010 - 31/12/2013

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 180400
Reference: RYC-2005-1561
Duration: 12/07/2006 - 31/10/2011

Altered autophagy in Huntington's disease

Inici, progressió i extensió de la Malaltia de Parkinson: rol de la neuromelanina, alfa-sinucleina i cossos de Lewy

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: AGAUR
Funding: 30000
Reference: 2011FI_B 00575
Duration: 01/02/2011 - 31/01/2014

Mecanismos y relevancia de la formación de cuerpos de Lewy en la Enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: Instituto de Salud Carlos III
Funding: 217679
Reference: PI071019
Duration: 01/01/2008 - 30/06/2011

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

Altered autophagy in Huntington's disease

Mecanismos y relevancia de la formación de cuerpos de Lewy en la Enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: Instituto de Salud Carlos III
Funding: 217679
Reference: PI071019
Duration: 01/01/2008 - 30/06/2011

Control de calidad de las mitocondrias: implicación en la enfermedad de Parkinson

IP: -
Collaborators: Annabelle Parent
Funding agency: Instituto de Salud Carlos III
Funding: 160325
Reference: PI09/00255
Duration: 01/01/2010 - 31/12/2013

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: EUROPEAN COMMISSION
Funding: 1151774.03
Reference: FP6-PEOPLE-PCD-IN-PD-24929
Duration: 01/12/2005 - 01/12/2009

Paper de la disfunció mitocondrial en la mort neuronal de la Malaltia de Parkinson.

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Fundació Bancària "la Caixa"
Funding: 90000
Reference: BM06-153-0
Duration: 01/01/2007 - 31/12/2009

Mecanismos y relevancia de la formación de cuerpos de Lewy en la Enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: Instituto de Salud Carlos III
Funding: 217679
Reference: PI071019
Duration: 01/01/2008 - 30/06/2011

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

Paper de la disfunció mitocondrial en la mort neuronal de la Malaltia de Parkinson.

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Fundació Bancària "la Caixa"
Funding: 90000
Reference: BM06-153-0
Duration: 01/01/2007 - 31/12/2009

Mecanismos y relevancia de la formación de cuerpos de Lewy en la Enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: Instituto de Salud Carlos III
Funding: 217679
Reference: PI071019
Duration: 01/01/2008 - 30/06/2011

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

Molecular mecanisms of neurodegeneration: targeting programmed cell death as a new therapeutic strategy for Parkinson's disease FP6 Grant No 006505 International Reintegration Grant. MIRG-CT-2004-006505

IP: Miquel Vila Bover
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2004-006505
Duration: 13/10/2005 - 13/10/2007

Paper de la disfunció mitocondrial en la mort neuronal de la Malaltia de Parkinson.

IP: Miquel Vila Bover
Collaborators: -
Funding agency: Fundació Bancària "la Caixa"
Funding: 90000
Reference: BM06-153-0
Duration: 01/01/2007 - 31/12/2009

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

Molecular mecanisms of neurodegeneration: targeting programmed cell death as a new therapeutic strategy for Parkinson's disease FP6 Grant No 006505 International Reintegration Grant. MIRG-CT-2004-006505

IP: Miquel Vila Bover
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2004-006505
Duration: 13/10/2005 - 13/10/2007

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

Molecular mecanisms of neurodegeneration: targeting programmed cell death as a new therapeutic strategy for Parkinson's disease FP6 Grant No 006505 International Reintegration Grant. MIRG-CT-2004-006505

IP: Miquel Vila Bover
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 80000
Reference: MIRG-CT-2004-006505
Duration: 13/10/2005 - 13/10/2007

Publications

Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations.

PMID: 35805133
Journal: Cells
Year: 2022
Reference: Cells. 2022 Jun 28;11(13). pii: cells11132046. doi: 10.3390/cells11132046.
Impact factor: 6.6
Publication type: Paper in international publication
Authors: Rodriguez-Urrutia, Amanda, Torres, Ines de, Santos-Briones, Ignacio, Azpiroz, Fernando, Lobo, Beatriz, Alonso-Cotoner, Carmen, Santos, Javier, Gonzalez-Castro, Ana M, Vicario, Maria, Guagnozzi, Danila et al.
DOI: 10.3390/cells11132046

Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction.

PMID: 35626681
Journal: Cells
Year: 2022
Reference: Cells. 2022 May 14;11(10). pii: cells11101644. doi: 10.3390/cells11101644.
Impact factor: 6.6
Publication type: Review in international publication
Authors: Salvo-Romero, Eloisa, Rodino-Janeiro, Bruno K, Albert-Bayo, Merce, Lobo, Beatriz, Santos, Javier, Farre, Ricard, Martinez, Cristina, Vicario, Maria et al.
DOI: 10.3390/cells11101644

Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase.

PMID: 35429504
Journal: NEUROPHARMACOLOGY
Year: 2022
Reference: Neuropharmacology. 2022 Jul 1;212:109058. doi: 10.1016/j.neuropharm.2022.109058. Epub 2022 Apr 13.
Impact factor: 5.251
Publication type: Paper in international publication
Authors: Gonzalez-Sepulveda, Marta, Omar, Muhammad Yusof, Hamdon, Sally, Ma, Guofen, Rosell-Vilar, Santi, Raivio, Noora, Abass, Doaa, Martinez-Rivas, Anna, Vila, Miquel, Giraldo, Jesus et al.
DOI: 10.1016/j.neuropharm.2022.109058

Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers.

PMID: 34794916
Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular
Year: 2022
Reference: Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Jan-Feb;41(1):52-54. doi: 10.1016/j.remnie.2021.05.002. Epub 2021 Nov 16.
Impact factor: 1.359
Publication type: Letter or abstract
Authors: Carrillo-Villamizar, E, Cardozo-Saavedra, A, Lorenzo-Bosquet, C, Lucas Del Pozo, S, Martinez-Saez, E, Hernandez-Vara, J et al.
DOI: 10.1016/j.remnie.2021.05.002

Present and Future Therapeutic Approaches to Barrier Dysfunction.

PMID: 34778332
Journal: Frontiers in Nutrition
Year: 2021
Reference: Front Nutr. 2021 Oct 28;8:718093. doi: 10.3389/fnut.2021.718093. eCollection 2021.
Impact factor: 6.576
Publication type: Review in international publication
Authors: Fortea, Marina, Albert-Bayo, Merce, Abril-Gil, Mar, Ganda Mall, John-Peter, Serra-Ruiz, Xavier, Henao-Paez, Alejandro, Exposito, Elba, Gonzalez-Castro, Ana Maria, Guagnozzi, Danila, Lobo, Beatriz et al.
DOI: 10.3389/fnut.2021.718093

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder.

PMID: 33986284
Journal: npj Parkinsons Disease
Year: 2021
Reference: NPJ Parkinsons Dis. 2021 May 13;7(1):40. doi: 10.1038/s41531-021-00184-9.
Impact factor: 8.651
Publication type: Paper in international publication
Authors: Yanes, Oscar, Laguna, Ariadna, Xicoy, Helena, Tolosa, Eduardo, Serradell, Monica, Vilas, Dolores, Gaig, Carles, Fernandez, Manel, Iranzo, Alex, Vila, Miquel et al.
DOI: 10.1038/s41531-021-00184-9

Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers.

PMID: 33875401
Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular
Year: 2021
Reference: Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Apr 16. pii: S2253-654X(21)00057-3. doi: 10.1016/j.remn.2021.02.015.
Impact factor: 1.359
Publication type: Letter or abstract
Authors: Hernandez-Vara, J, Martinez-Saez, E, Lucas Del Pozo, S, Cardozo-Saavedra, A, Carrillo-Villamizar, E, Lorenzo-Bosquet, C et al.
DOI: 10.1016/j.remn.2021.02.015

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults.

PMID: 33738725
Journal: ADVANCES IN THERAPY
Year: 2021
Reference: Adv Ther. 2021 May;38(5):2054-2076. doi: 10.1007/s12325-021-01676-z. Epub 2021 Mar 18.
Impact factor: 3.847
Publication type: Review in international publication
Authors: Alonso-Cotoner, Carmen, Abril-Gil, Mar, Albert-Bayo, Merce, Mall, John-P Ganda, Exposito, Elba, Gonzalez-Castro, Ana M, Lobo, Beatriz, Santos, Javier et al.
DOI: 10.1007/s12325-021-01676-z

The Emerging Role of the Lysosome in Parkinson's Disease.

PMID: 33147750
Journal: Cells
Year: 2020
Reference: Cells. 2020 Nov 2;9(11). pii: cells9112399. doi: 10.3390/cells9112399.
Impact factor: 4.366
Publication type: Review in international publication
Authors: Navarro-Romero, Alba, Montpeyo, Marta, Martinez-Vicente, Marta et al.
DOI: 10.3390/cells9112399

CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.

PMID: 33118032
Journal: BRAIN
Year: 2020
Reference: Brain. 2020 Dec 1;143(12):3717-3733. doi: 10.1093/brain/awaa269.
Impact factor: 11.337
Publication type: Paper in international publication
Authors: Galiano-Landeira, Jordi, Torra, Albert, Vila, Miquel, Bove, Jordi et al.
DOI: 10.1093/brain/awaa269

Validation of a Reversed Phase UPLC-MS/MS Method to Determine Dopamine Metabolites and Oxidation Intermediates in Neuronal Differentiated SH-SY5Y Cells and Brain Tissue.

PMID: 32786306
Journal: ACS Chemical Neuroscience
Year: 2020
Reference: ACS Chem Neurosci. 2020 Sep 2;11(17):2679-2687. doi: 10.1021/acschemneuro.0c00336. Epub 2020 Aug 24.
Impact factor: 4.486
Publication type: Paper in international publication
Authors: Nicolau, Alba, Guillard-Sirieix, Camille, Xicoy, Helena, Kobayashi, Jumpei, Vila, Miquel, Compte, Joan, Penuelas, Nuria, Cuadros, Thais, Gonzalez-Sepulveda, Marta, Laguna, Ariadna et al.
DOI: 10.1021/acschemneuro.0c00336

BDNF levels and nigrostriatal degeneration in "drug naive" Parkinson's disease patients. An "in vivo" study using I-123-FP-CIT SPECT.

PMID: 32682292
Journal: PARKINSONISM & RELATED DISORDERS
Year: 2020
Reference: Parkinsonism Relat Disord. 2020 Sep;78:31-35. doi: 10.1016/j.parkreldis.2020.06.037. Epub 2020 Jul 4.
Impact factor: 3.926
Publication type: Paper in international publication
Authors: Lucas-Del Pozo, S, Carter, S, Armengol-Bellapart, M, Castell-Conesa, J, Cuberas-Borros, G, Corominas-Roso, M, Lorenzo-Bosquet, C, Saez-Francas, N, Hernandez-Vara, J et al.
DOI: 10.1016/j.parkreldis.2020.06.037

Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.

PMID: 31731485
Journal: Cells
Year: 2019
Reference: Cells. 2019 Oct 25;8(11). pii: cells8111317. doi: 10.3390/cells8111317.
Impact factor: 5.656
Publication type: Review in international publication
Authors: Xicoy, Helena, Penuelas, Nuria, Vila, Miquel, Laguna, Ariadna et al.
DOI: 10.3390/cells8111317

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.

PMID: 30846695
Journal: Nature Communications
Year: 2019
Reference: Nat Commun. 2019 Mar 7;10(1):973. doi: 10.1038/s41467-019-08858-y.
Impact factor: 11.878
Publication type: Paper in international publication
Authors: Gonzalez-Sepulveda, Marta, Penuelas, Nuria, Torra, Albert, Rodriguez-Galvan, Beatriz, Ballabio, Andrea, Hasegawa, Takafumi, Bortolozzi, Analia, Gelpi, Ellen, Vila, Miquel, Parent, Annabelle et al.
DOI: 10.1038/s41467-019-08858-y

Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis.

PMID: 30744042
Journal: Cells
Year: 2019
Reference: Cells. 2019 Feb 8;8(2). pii: cells8020135. doi: 10.3390/cells8020135.
Impact factor: 5.656
Publication type: Review in national publication
Authors: Albert-Bayo, Merce, Paracuellos, Irene, Gonzalez-Castro, Ana M, Rodriguez-Urrutia, Amanda, Rodriguez-Lagunas, Maria J, Alonso-Cotoner, Carmen, Santos, Javier, Vicario, Maria et al.
DOI: 10.3390/cells8020135

Metabolic adaptation in the human gut microbiota during pregnancy and the first year of life.

PMID: 30415891
Journal: EBioMedicine
Year: 2019
Reference: EBioMedicine. 2019 Jan;39:497-509. doi: 10.1016/j.ebiom.2018.10.071. Epub 2018 Nov 8.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Gosalbes, Maria Jose, Compte, Joan, Moriano-Gutierrez, Silvia, Valles, Yvonne, Jimenez-Hernandez, Nuria, Pons, Xavier, Artacho, Alejandro, Francino, M Pilar et al.
DOI: 10.1016/j.ebiom.2018.10.071

Thesis

Etiopathogenic relevance of CD8+ T cells in Parkinson's disease

PhD student: Jordi Galiano Landeira
Director/s: Jordi Bove Badell
University: Universitat Autònoma de Barcelona
Year: 2021

Transcription factor eb-mediated neurotrophic and neuroprotective effects: relevance to parkinson's disease

PhD student: Albert Torra i Talavera
Director/s: Jordi Bove Badell, Miquel Vila Bover
University: Universitat Autònoma de Barcelona
Year: 2019

Transcription factor eb-mediated neurotrophic and neuroprotective effects: relevance to parkinson's disease

PhD student: Albert Torra i Talavera
Director/s: Jordi Bove Badell, Miquel Vila Bover
University: Universitat Autònoma de Barcelona
Year: 2019

Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson's disease and Huntington's disease

PhD student: Sandra Franco Iborra
Director/s: Miquel Vila Bover
University: Universitat Autònoma de Barcelona
Year: 2018

Noves formes farmacèutiques i vies d'administració de Levodopa per al tractament de la malaltia de Parkinson: nou anys d'experiència en infusió intraduodenal del gel de Levodopa/Carbidopa Tutor: Dr. José Rodríguez Álvarez

PhD student: Oriol de Fabregues-Boixar Nebot
Director/s: Francesc Miquel Rodriguez, Miquel Vila Bover
University: Universitat Autònoma de Barcelona
Year: 2016

Blog

News

Investigadors del grup de Malalties Neurodegeneratives del VHIR

A Vall d'Hebron study advances in the knowledge of the biological basis of Parkinson's disease

Researchers describe the molecular mechanisms by which the GBA gene, the main genetic risk factor, associates with the accumulation of α-synuclein in neurons.

A research project into Parkinson’s disease by Dr Marta Martínez-Vicente awarded a CaixaResearch Health Research 2022 grant

It is the project “New Nanotechnological Therapy for Parkinson’s disease: Nose to Brain Delivery of GBA-Polymer Nanoconjugates (nanoGBAtoBrain)”.

Pacients i professionals de Vall d’Hebron units per a la recerca del Parkinson

La primera jornada dedicada a aquesta malaltia organitzada pel Campus Vall d’Hebron ha reunit més de 150 assistents.

Job offers

Licensed Research Technician - Neurodegenerative Diseases Research Group

Start date:

16/12/2022

End date:

30/12/2022

Document: Download

Predoctoral Researcher

Start date:

10/11/2022

End date:

25/11/2022

Document: Download

Posdoctoral Researcher

Start date:

09/09/2022

End date:

23/09/2022

Document: Download

Coneix i participa al projecte VHIP

Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.

Access the project and study